课题基金 / 基金详情

From Rational Design To in vivo Evaluation of Dual Covalent Prolyl Oligopeptidase / Fibroblast Activation Protein Inhibitors as Potential Cancer Therapeutics.

From Rational Design To in vivo Evaluation of Dual Covalent Prolyl Oligopeptidase / Fibroblast Activation Protein Inhibitors as Potential Cancer Therapeutics.
从合理设计到双共价脯氨酰寡肽酶/成纤维细胞激活蛋白抑制剂作为潜在癌症治疗药物的体内评估。
批准号：
304789
负责人：
Moitessier Nicolas R
金额：
$27.05万
依托单位：
McGill University
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2014
资助国家：
加拿大
项目状态：
已结题
起止时间：
2014-03-01 至 2017-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=304789&lang=en
关键词：
Animal Models Cancer Therapeutics Computer-Aided Drug Design Fibroblast Activation Protein In Vivo Testing Medicinal Chemistry Nmr Spectroscopy Organic Synthesis Prolyl Oligopeptidase

项目摘要

项目成果

Moitessier Nicolas R的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Proline oligopeptidase (POP), and fibroblast activation protein-alpha (FAP), are large homologous enzymes. POP has been a target for potential neurodegenerative diseases therapeutics. More recenlty, cancer cells were found to exhibit elevated levels of P
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COVID-19 Variant Supplement - Development of COVID-2019 main protease inhibitors as potential antivirals against the 2019 coronavirus.
  • 批准号：
    443278
  • 项目类别：
    Operating Grants
  • 资助金额：
    $3.64万
  • 财政年份：
    2021
  • 负责人：
    Moitessier Nicolas R
  • 依托单位：
    McGill University
Development of COVID-2019 main protease inhibitors as potential antivirals against the 2019 coronavirus.
  • 批准号：
    422713
  • 项目类别：
    Operating Grants
  • 资助金额：
    $14.79万
  • 财政年份：
    2020
  • 负责人：
    Moitessier Nicolas R
  • 依托单位：
    McGill University
海外基金